New radiation approach aims to tame pancreatic cancer with fewer side effects
NCT ID NCT04452357
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of radiation called pulsed low-dose-rate (PLDR) for people with pancreatic cancer that cannot be removed right away. The radiation is given in small, spaced-out bursts along with the chemotherapy drug gemcitabine. The goal is to see if this approach causes fewer stomach and bowel side effects than standard radiation. Only 12 participants are being studied to check safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PLDR radiation and gemcitabine
What this could lead to
If successful, this could lead to a safer way to shrink pancreatic tumors before surgery, with fewer side effects than standard radiation.
What could go wrong
This is a very early, small phase I trial with only 12 participants. It primarily tests safety, not effectiveness, and may not work or benefit future patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States